Hematology

Researchers have developed the ALA-CART platform to enhance CAR T cell therapy’s effectiveness against antigen-low leukemias.

A new study shows that GLP-1 receptor agonists (GLP-1RAs) could significantly reduce the risk of developing hematologic cancers in patients with Type 2 diabetes.

A study of 783 patients in 38 T cell therapy trials reveals reassuring results about the long-term safety of gene therapies for HIV-1 and cancer, with only 2.3% developing secondary malignancies.

Universal genetic testing for haemoglobinopathies can enhance early detection and health equity in newborn screening programmes worldwide.

CAR T-cell therapy for B-cell lymphoma shows a positive long-term safety profile with few late complications.

Recent research highlights the significant underuse of disease-modifying therapies for sickle cell disease, despite their established benefits in reducing pain and preventing organ damage.

Multiple myeloma patients with two or more high-risk genetic abnormalities face significantly poorer outcomes, regardless of disease stage or treatment.

Bleeding risk from anticoagulants varies by gender and age in venous thromboembolism treatment, especially during the initial phase.